Real world clinical outcomes of palbociclib in hormone receptor positive (HR plus ) metastatic breast cancer (MBC) patients.

被引：3
|
作者：
Eziokwu, Akaolisa Samuel
Varella, Leticia
Kruse, Megan Lynn
Jia, Xuefei
Moore, Halle C. F.
Budd, George Thomas
Abraham, Jame
Montero, Alberto J.
机构：
[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA
[2] Weill Cornell Med, Dept Hematol Oncol, New York, NY USA
[3] Cleveland Clin, Dept Hematol Oncol, Cleveland, OH USA
[4] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA
[5] Cleveland Clin, Cleveland, OH USA
[6] NSABP Fdn, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical characteristics, demographics, and outcomes in hormone-receptor (HR plus ) positive metastatic breast cancer (MBC) patients treated with palbociclib.
    Landry, Chrystal Ann
    Dimitrova, Maya
    Ru, Meng
    Teplinsky, Eleonora
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Real world experience of palbociclib in hormone receptor-positive metastatic breast cancer.
    Malik, Faizan
    Ali, Naveed
    Jafri, Syed Imran Mustafa
    Sundermeyer, Mark L.
    Seidman, Michael Jeffrey
    Fidler, Christian Joseph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Redana, Stefania
    Papadimitraki, Elisavet
    Okonji, David Odhiambo
    Khabra, Komel
    Thanopoulou, Eirini
    Chiramel, Jaseela
    Papanastasopoulos, Panagiotis
    Wardley, Andrew M.
    Hogg, Martin S.
    Howell, Sacha Jon
    Zucchini, Giorgia
    Kenny, Laura M.
    Ring, Alistair E.
    Johnston, Stephen R. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC)
    Twelves, C.
    Cheeseman, S.
    Thompson, M.
    Riaz, M.
    Perren, T.
    Ahat-Donker, N.
    Sopwith, W.
    Myland, M.
    Lee, A.
    Turner, S.
    Hall, G.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [5] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Real world data on use of palbociclib in hormone-receptor (ER) positive HER2 negative metastatic breast cancer (MBC) among Asian patients
    Chiu, J.
    Leung, R.
    Sze, H.
    Teo, P.
    Choi, P.
    Lam, T-C.
    Yau, T.
    Cheng, P.
    Cheung, F-Y.
    Cheung, P.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) plus /- pembrolizumab (P) for hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    de Sousa, Romualdo Barroso
    Ajami, Nadim
    Keenan, Tanya E.
    Andrews, Chelsea
    Pittenger, Jessica L.
    Wulf, Gerburg
    Spring, Laura
    Krop, Ian E.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [8] Impact of early dose reduction of palbociclib on clinical outcomes in patients with hormone-receptor positive metastatic breast cancer
    Moftakhar, Bahar
    Lekkala, Manidhar Reddy
    Strawderman, Myla
    Smith, Tae C.
    Meacham, Philip
    Fitzgerald, Bryan
    Dhakal, Ajay
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [9] Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Lim, Joline Si Jing
    Wong, Andrea
    Ow, Samuel Guan Wei
    Ngoi, Natalie
    Ang, Yvonne Li'en
    Chan, Gloria
    Eng, Lim Siew
    Chong, Wan Qin
    Choo, Joan
    Lee, Matilda
    Tan, Hon Lyn
    Jan, Yi-hua
    Tan, Kien Thiam
    Sundar, Raghav
    Tan, David Shao Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Yong, Wei-Peng
    Goh, Boon C.
    Lee, Soo-Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    [J]. CANCER RESEARCH, 2023, 83 (05)
12345